Watson to acquire portfolio of divested generic pharmaceutical products

Download PDF Copy

Jul 28 2011

NewsGuard 100/100 Score

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced a definitive agreement to acquire a portfolio of generic pharmaceutical products that are being divested as a result of the merger between Perrigo Company and Paddock Laboratories. The portfolio consists of six products, including four FDA-approved products and two undisclosed development-stage products. Commercialized products in the portfolio include:

Ciclopirox shampoo 1%
Ammonium Lactate Cream 12%
Ammonium Lactate Lotion 12%
Promethazine HCl Suppositories 12.5 and 25 mg

Perrigo will supply the products to Watson under a Manufacturing and Supply Agreement until manufacturing is transferred to Watson or a third party. Additional details, including financial terms, have not been disclosed.

Source:

Watson Pharmaceuticals, Inc.

Posted in: Business / Finance | Pharmaceutical News

Tags: Manufacturing, Medicaid, Medicare, Pharmaceuticals, Urology

Comments (0)

Download PDF Copy

Suggested Reading

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tertiary lymphoid structures linked to improved outcomes in liver cancer patients

Tiny molecule offers hope in reducing opioid side effects

Tiny molecule offers hope in reducing opioid side effects

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

Healthy lifestyle choices can offset genetic risk for brain diseases

Healthy lifestyle choices can offset genetic risk for brain diseases

Study focuses on COPD progression in younger populations

Study focuses on COPD progression in younger populations

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Obesity medication liraglutide is safe and effective in children aged 6 to <12 years

Urine RNA analysis shows promise for detecting genitourinary diseases

Urine RNA analysis shows promise for detecting genitourinary diseases

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

Post

Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net.

To start a conversation, please log into your AZoProfile account first, or create a new account.

Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content.

A few things you need to know before we start. Please read and accept to continue.

Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI.
Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy.
Large Language Models can make mistakes. Consider checking important information.

I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements.

Please check the box above to proceed.

Great. Ask your question.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...

Study shows how a single defective BRCA1 gene accelerates cancer development